{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:57:28Z","timestamp":1794650248054,"version":"4.9.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T00:00:00Z","timestamp":1765670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1226524 N-7029"],"award-info":[{"award-number":["1226524 N-7029"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["AKUL15-30\/G0H1216N"],"award-info":[{"award-number":["AKUL15-30\/G0H1216N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["I000123N"],"award-info":[{"award-number":["I000123N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004497","name":"Onderzoeksraad, KU Leuven","doi-asserted-by":"publisher","award":["C\/2020\/1528"],"award-info":[{"award-number":["C\/2020\/1528"]}],"id":[{"id":"10.13039\/501100004497","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI radiopharm. chem."],"DOI":"10.1186\/s41181-025-00411-1","type":"journal-article","created":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T07:56:21Z","timestamp":1765698981000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["cGMP-compliant high-yield automated production of [18F]AlF-FAPI-74: optimization of quality control and evaluation of molar dose impact"],"prefix":"10.1186","volume":"11","author":[{"given":"Ward","family":"Storms","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Celen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Maes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Serdons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolien","family":"Goffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjibbe","family":"De Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Trump","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corentin","family":"Warnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"Gendron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romaric","family":"G\u00e9rardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Van Laere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe M.","family":"Deroose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janke","family":"Kleynhans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3692-1608","authenticated-orcid":false,"given":"Frederik","family":"Cleeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,14]]},"reference":[{"issue":"9","key":"411_CR1","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/jamaoncol.2023.0265","volume":"9","author":"HK Litt","year":"2023","unstructured":"Litt HK, Kwon DH, Velazquez AI. FDG PET scans in cancer care. JAMA Oncol. 2023;9(9):1304. https:\/\/doi.org\/10.1001\/jamaoncol.2023.0265.","journal-title":"JAMA Oncol"},{"issue":"3","key":"411_CR2","doi-asserted-by":"publisher","first-page":"480","DOI":"10.2967\/jnumed.107.047787","volume":"49","author":"JW Fletcher","year":"2008","unstructured":"Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe V, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49(3):480\u2013508.","journal-title":"J Nucl Med"},{"key":"411_CR3","doi-asserted-by":"publisher","first-page":"648187","DOI":"10.3389\/fonc.2021.648187","volume":"11","author":"L Xin","year":"2021","unstructured":"Xin L, Gao J, Zheng Z, Chen Y, Lv S, et al. Fibroblast activation protein-\u0251 as a target in the bench-to-bedside diagnosis and treatment of tumors: a narrative review. Front Oncol. 2021;11:648187. https:\/\/doi.org\/10.3389\/fonc.2021.648187.","journal-title":"Front Oncol"},{"key":"411_CR4","doi-asserted-by":"crossref","unstructured":"Mori Y et al. Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET). NPJ Imaging 2024 2:1 2, 1\u201321 (2024).","DOI":"10.1038\/s44303-024-00053-z"},{"issue":"2","key":"411_CR5","doi-asserted-by":"publisher","first-page":"160","DOI":"10.2967\/jnumed.120.244806","volume":"62","author":"A Altmann","year":"2021","unstructured":"Altmann A, Haberkorn U, Siveke J. The latest developments in imaging of fibroblast activation protein. J Nucl Med. 2021;62(2):160\u20137. https:\/\/doi.org\/10.2967\/jnumed.120.244806.","journal-title":"J Nucl Med"},{"issue":"1","key":"411_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2967\/jnumed.124.269002","volume":"66","author":"TA Hope","year":"2025","unstructured":"Hope TA, Calais J, Goenka AH, Haberkorn U, Konijnenberg M, et al. SNMMI procedure Standard\/EANM practice guideline for fibroblast activation protein (FAP) PET. J Nucl Med. 2025;66(1):26\u201333. https:\/\/doi.org\/10.2967\/jnumed.124.269002.","journal-title":"J Nucl Med"},{"key":"411_CR7","doi-asserted-by":"publisher","first-page":"4694","DOI":"10.7150\/thno.88335","volume":"13","author":"D Ruan","year":"2023","unstructured":"Ruan D, et al. Evaluation of FAPI PET imaging in gastric cancer: a systematic review and meta-analysis. Theranostics. 2023;13:4694\u2013710.","journal-title":"Theranostics"},{"key":"411_CR8","doi-asserted-by":"crossref","unstructured":"van Veldhuijzen SEM et al. FAPI PET versus FDG PET, CT or MRI for staging Pancreatic-, Gastric- and cholangiocarcinoma: systematic review and Head-to-Head comparisons of diagnostic performances. Diagnostics (Basel) 12, (2022).","DOI":"10.3390\/diagnostics12081958"},{"key":"411_CR9","doi-asserted-by":"publisher","first-page":"779","DOI":"10.2967\/jnumed.120.253062","volume":"62","author":"M R\u00f6hrich","year":"2021","unstructured":"R\u00f6hrich M, et al. Impact of 68 Ga-FAPI PET\/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas. J Nucl Med. 2021;62:779\u201386.","journal-title":"J Nucl Med"},{"key":"411_CR10","doi-asserted-by":"publisher","unstructured":"Ding J et al. Prognostic value of preoperative [ 68 Ga]Ga-FAPI-04 PET\/CT in patients with resectable pancreatic ductal adenocarcinoma in correlation with Immunohistological characteristics. https:\/\/doi.org\/10.1007\/s00259-022-06100-4","DOI":"10.1007\/s00259-022-06100-4"},{"key":"411_CR11","unstructured":"Karbhari A et al. Phase 2, Multicenter, single Arm, open label Non-Randomized study of [68Ga]FAPI-46 PET in patients with resectable or borderline resectable pancreatic ductal carcinoma. J Nucl Med 64, (2023)."},{"key":"411_CR12","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.2967\/jnumed.122.264827","volume":"64","author":"L Kessler","year":"2023","unstructured":"Kessler L, et al. 68 Ga-Labeled fibroblast activation protein inhibitor (68 Ga-FAPI) PET for pancreatic adenocarcinoma: data from the 68 Ga-FAPI PET observational trial. J Nucl Med. 2023;64:1910\u20137.","journal-title":"J Nucl Med"},{"key":"411_CR13","first-page":"123","volume":"26","author":"M Jiao","year":"2023","unstructured":"Jiao M, Mingsong T, Hao J, Chunyin Z. Diagnostic value of 18F-FDG PET\/CT and 68Ga-FAPI PET\/CT in primary liver cancer: A systematic review and meta-analysis. Hell J Nucl Med. 2023;26:123\u201331.","journal-title":"Hell J Nucl Med"},{"key":"411_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/S00261-024-04266-Z","author":"Z Zhuang","year":"2024","unstructured":"Zhuang Z, Zhang Y, Yang X, Deng X, Wang Z. Head-to-head comparison of the diagnostic performance between 68Ga-FAPI-04 PET\/CT and 18F-FDG PET\/CT in colorectal cancer: a systematic review and meta-analysis. Abdom Radiol (NY). 2024. https:\/\/doi.org\/10.1007\/S00261-024-04266-Z.","journal-title":"Abdom Radiol (NY)"},{"key":"411_CR15","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s12149-023-01852-x","volume":"37","author":"L Evangelista","year":"2023","unstructured":"Evangelista L, Filippi L, Schillaci O. What radiolabeled FAPI pet can add in breast cancer? A systematic review from literature. Ann Nucl Med. 2023;37:442\u201350.","journal-title":"Ann Nucl Med"},{"key":"411_CR16","doi-asserted-by":"crossref","unstructured":"Rizzo A et al. Diagnostic yield of FAP-guided positron emission tomography in thyroid cancer: a systematic review. Front Med (Lausanne) 11, (2024).","DOI":"10.3389\/fmed.2024.1381863"},{"key":"411_CR17","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s00330-023-10013-7","volume":"34","author":"Q Yang","year":"2024","unstructured":"Yang Q, et al. Performance of [18F]FDG PET\/CT versus FAPI PET\/CT for lung cancer assessment: a systematic review and meta-analysis. Eur Radiol. 2024;34:1077\u201385.","journal-title":"Eur Radiol"},{"key":"411_CR18","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2967\/jnumed.123.266556","volume":"65","author":"B Gu","year":"2024","unstructured":"Gu B, et al. Imaging of tumor stroma using 68 Ga-FAPI PET\/CT to improve diagnostic accuracy of primary tumors in head and neck cancer of unknown primary: A comparative imaging trial. J Nucl Med. 2024;65:365\u201371.","journal-title":"J Nucl Med"},{"key":"411_CR19","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1007\/s00259-022-06095-y","volume":"50","author":"Q Shu","year":"2023","unstructured":"Shu Q, et al. The additional role of [68Ga]Ga-FAPI-04 PET\/CT in patients with unknown primary lesions with a negative or equivocal [18F]FDG. Eur J Nucl Med Mol Imaging. 2023;50:1442\u201352.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"411_CR20","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1007\/s00259-020-05055-8","volume":"48","author":"S Serfling","year":"2021","unstructured":"Serfling S, et al. Improved cancer detection in waldeyer\u2019s tonsillar ring by 68 Ga-FAPI PET\/CT imaging. Eur J Nucl Med Mol Imaging. 2021;48:1178\u201387.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"411_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00259-021-05488-9","volume":"49","author":"K Dendl","year":"2022","unstructured":"Dendl K, et al. FAP imaging in rare cancer entities-first clinical experience in a broad spectrum of malignancies. Eur J Nucl Med Mol Imaging. 2022;49:7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"411_CR22","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.cpet.2023.02.010","volume":"18","author":"S Mosessian","year":"2023","unstructured":"Mosessian S, Jensen JD, Enke AS. Current state of clinical trials and regulatory approvals with fibroblast activation protein targeting interventions. PET Clin. 2023;18:429\u201339.","journal-title":"PET Clin"},{"key":"411_CR23","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00259-024-06986-2","volume":"52","author":"K Zhong","year":"2025","unstructured":"Zhong K, et al. Comparison of [18F]FAPI-42 and [18F]FDG PET\/CT in the evaluation ofsystemic vasculitis. Eur J Nucl Med Mol Imaging. 2025;52:1083\u201394.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"411_CR24","doi-asserted-by":"crossref","unstructured":"Mori Y et al. FAPI PET: fibroblast activation protein inhibitor use in oncologic and nononcologic disease. Radiology 306, (2023).","DOI":"10.1148\/radiol.220749"},{"key":"411_CR25","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1053\/j.semnuclmed.2023.02.001","volume":"53","author":"M Bentestuen","year":"2023","unstructured":"Bentestuen M, Al-Obaydi N, Zacho HD. FAPI-avid nonmalignant PET\/CT findings: an expedited systematic review. Semin Nucl Med. 2023;53:694\u2013705.","journal-title":"Semin Nucl Med"},{"issue":"6","key":"411_CR26","doi-asserted-by":"publisher","first-page":"835","DOI":"10.2967\/jnumed.123.265622","volume":"64","author":"H Leupe","year":"2023","unstructured":"Leupe H, Ahenkorah S, Dekervel J, Unterrainer M, Van Cutsem E, Verslype C, Cleeren F, Deroose CM. 18F-Labeled somatostatin analogs as PET tracers for the somatostatin receptor: ready for clinical use. J Nucl Med. 2023;64(6):835\u201341. https:\/\/doi.org\/10.2967\/jnumed.123.265622.","journal-title":"J Nucl Med"},{"issue":"1","key":"411_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40658-016-0144-5","volume":"3","author":"M Conti","year":"2016","unstructured":"Conti M, Eriksson L. Physics of pure and non-pure positron emitters for PET: a review and a discussion. EJNMMI Phys. 2016;3(1):8. https:\/\/doi.org\/10.1186\/s40658-016-0144-5.","journal-title":"EJNMMI Phys"},{"key":"411_CR28","doi-asserted-by":"publisher","first-page":"118103","DOI":"10.1016\/j.ejmech.2025.118103","volume":"299","author":"C Hoffmann","year":"2025","unstructured":"Hoffmann C, Gr\u00f6ner B, Bahutski V, Endepols H, Lindemeyer J, Saniternik S, Drewes B, Timmer M, Gokhadze O, Brugger M, Neumaier F, Neumaier B, Zlatopolskiy BD. Comparative evaluation of three 18F-fluorinated FAP ligands in rodent tumor models. Eur J Med Chem. 2025;299:118103. https:\/\/doi.org\/10.1016\/j.ejmech.2025.118103.","journal-title":"Eur J Med Chem"},{"issue":"8","key":"411_CR29","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1021\/acs.bioconjchem.5c00366","volume":"36","author":"K Adhikari","year":"2025","unstructured":"Adhikari K, Grintsevich S, de Groot A, Verhulst E, van Rymenant Y, Vangestel C, Lauwerys L, Miranda A, De Meester I, Van der Veken P, Elvas F. Synthesis and preclinical evaluation of druglike 18F-Labeled fibroblast activation protein (FAP) inhibitors with enhanced tumor retention. Bioconjug Chem. 2025;36(8):1887\u2013906. https:\/\/doi.org\/10.1021\/acs.bioconjchem.5c00366.","journal-title":"Bioconjug Chem"},{"key":"411_CR30","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/RLU.0000000000002578","volume":"44","author":"WJ McBride","year":"2019","unstructured":"McBride WJ, Sharkey RM, Karacay H, D\u2019Souza CA, Rossi EA, Laverman P, et al. Novel method of 18F radiolabelling for PET\/CT for imaging neuroendocrine neoplasms. Clin Nucl Med. 2019;44:452\u20138.","journal-title":"Clin Nucl Med"},{"key":"411_CR31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s41181-021-00141-0","volume":"6","author":"SJ Archibald","year":"2021","unstructured":"Archibald SJ, Allot L. The aluminum-[18F]fluoride revolution: simple radiochemistry with a big impact for radiolabelled biomolecules. EJNMMI Radiopharm Chem. 2021;6:30. https:\/\/doi.org\/10.1186\/s41181-021-00141-0.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"411_CR32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/molecules24162866","volume":"24","author":"C Fersing","year":"2019","unstructured":"Fersing C, Bouhlel A, Cantelli C, Garrigue P, Lisowski V, Guillet B. A comprehensive review of non-covalent radiofluorination approaches using aluminum [18F]fluoride: will [18F]AlF replace 68Ga for metal chelate labeling? Molecules. 2019;24:16. https:\/\/doi.org\/10.3390\/molecules24162866.","journal-title":"Molecules"},{"key":"411_CR33","doi-asserted-by":"publisher","unstructured":"Giesel FL, Adeberg S, Syed M, Lindner T, Jiminez-franco LD, Mavriopoulou E et al. FAPI-74 PET\/CT using either 18F-AlF or cold-kit 68Ga-labelling: biodistribution, radiation dosimetry and tumor delineation in lung cancer patients. J Nucl Med 62(2): 201\u20137. https:\/\/doi.org\/10.2967\/jnumed.120.245084","DOI":"10.2967\/jnumed.120.245084"},{"key":"411_CR34","doi-asserted-by":"publisher","unstructured":"Wang S, Zhou X, Xu C, Ding J, Liu S, Hou X et al. Clinical translation evaluation of Al18F-NOTA-FAPI for fibroblast activation protein-targeted tumour imaging. Eur J Nucl Med Mol Imaging. 48(13): 4259\u201371. https:\/\/doi.org\/10.1007\/s00259-021-05470-5","DOI":"10.1007\/s00259-021-05470-5"},{"key":"411_CR35","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s41181-021-00142-z","volume":"6","author":"S Naka","year":"2021","unstructured":"Naka S, Watabe T, Lindner T, Cardinale J, Kurimoto K, Moore M, et al. One-pot and one-step automated radio-synthesis of [18F]AlF-FAPI-74 using a multi-purpose synthesizer: a proof-of-concept experiment. EJNMMI Radiopharmacy Chem. 2021;6:28. https:\/\/doi.org\/10.1186\/s41181-021-00142-z.","journal-title":"EJNMMI Radiopharmacy Chem"},{"key":"411_CR36","doi-asserted-by":"publisher","unstructured":"Dahl K, Kissing E, Bylund L, Moein MM, Samen E, Tran T. Fully automated production of the fibroblast activation protein Radiotracer [18F]FAPI-74. J Label Comp Radiopharm, 64(8): 346\u201352. https:\/\/doi.org\/10.1002\/jlcr.3926","DOI":"10.1002\/jlcr.3926"},{"key":"411_CR37","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jpba.2015.04.009","volume":"111","author":"D Ory","year":"2015","unstructured":"Ory D, Van den Branden J, De Groot T, Serdons K, Bex M, Declercq L, et al. Retention of [18F] fluoride on reversed-phase HPLC columns. J Pharm Biomed Anal. 2015;111:209\u201314.","journal-title":"J Pharm Biomed Anal"},{"issue":"6","key":"411_CR38","doi-asserted-by":"publisher","first-page":"862","DOI":"10.2967\/jnumed.121.263016","volume":"63","author":"L Zhao","year":"2022","unstructured":"Zhao L, Niu B, Fang J, Pang Y, Li S, Xie C, Sun L, et al. Synthesis, preclinical evaluation, and a pilot clinical PET imaging study of 68Ga-labeled FAPI dimer. J Nucl Med. 2022;63(6):862\u20138. https:\/\/doi.org\/10.2967\/jnumed.121.263016.","journal-title":"J Nucl Med"},{"key":"411_CR39","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s00259-024-06969-3","volume":"52","author":"A Galbiati","year":"2025","unstructured":"Galbiati A, Bocci M, Neri D, Cazzamalli S. Effect of molar dose on the in vivo tissue biodistribution profile of FAP-targeted radioligand therapeutics. EJNMMI. 2025;52:1339\u2013405. https:\/\/doi.org\/10.1007\/s00259-024-06969-3.","journal-title":"EJNMMI"},{"key":"411_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07071-y","author":"L Liu","year":"2025","unstructured":"Liu L, Shi Y, He S, Yang J, Song S, Wang D, Et al. The molar dose of FAPI administered impacts on the FAP-targeted PET imaging and therapy in mouse synergistic tumor models. EJNMMI. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07071-y.","journal-title":"EJNMMI"},{"issue":"1","key":"411_CR41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s41181-019-0084-1","volume":"5","author":"T Tshibangu","year":"2020","unstructured":"Tshibangu T, Cawthorne C, Serdons K, Pauwels E, Gsell W, Bormans G, Deroose CM, Cleeren F. Automated GMP compliant production of [18F]AlF-NOTA-octreotide. EJNMMI Radiopharm Chem. 2020;5(1):4. https:\/\/doi.org\/10.1186\/s41181-019-0084-1.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"411_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2023.108338","author":"S Ahenkorah","year":"2023","unstructured":"Ahenkorah S, Cawthorne C, Murce E, Deroose CM, Cardinaels T, Seimbille, et al. Nucl Med Biol. 2023;118\u20139. https:\/\/doi.org\/10.1016\/j.nucmedbio.2023.108338. Direct comparison of [18F]AlF-NOTA-JR11 and [18F]AlF-NOTA-octreotide for PET imaging of neuroendocrine tumors: antagonist versus agonist."},{"key":"411_CR43","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12917-020-02451-y","volume":"16","author":"NP Du Sert","year":"2020","unstructured":"Du Sert NP, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. BMC Vet Res. 2020;16:242. https:\/\/doi.org\/10.1186\/s12917-020-02451-y.","journal-title":"BMC Vet Res"},{"issue":"2","key":"411_CR44","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1134\/s1066362223020030","volume":"65","author":"RN Krasikova","year":"2023","unstructured":"Krasikova RN. Fluorine-18 or gallium-68: the perspective of the PET radiochemist. Radiochemistry. 2023;65(2):158\u201376. https:\/\/doi.org\/10.1134\/s1066362223020030.","journal-title":"Radiochemistry"},{"key":"411_CR45","doi-asserted-by":"publisher","unstructured":"Kesch c, Kratochwil C, Mier W, Kopka K, Giesel FL. 68Ga or 18F for prostate cancer imaging. J Nucl Med, 58(5): 687\u20138. https:\/\/doi.org\/10.2967\/jnumed.117.190157","DOI":"10.2967\/jnumed.117.190157"},{"key":"411_CR46","doi-asserted-by":"crossref","unstructured":"International Council for Harmonisation guideline on analytical validation (ICH Q2 (R1)). 2019: https:\/\/database.ich.org\/sites\/default\/files\/Q2_R1__Guideline.pdf","DOI":"10.47583\/gjfpas.2020.v01i06.001"},{"issue":"3","key":"411_CR47","doi-asserted-by":"publisher","first-page":"16264","DOI":"10.1021\/acs.molpharmceut.4c01360","volume":"22","author":"L Bian","year":"2025","unstructured":"Bian L, Liu x, Wang X, Sun Y, Du X, et al. Preclinical and first-in-human imaging of novel [18F]F-FAPI-FUSCC-07 tracer: comparative prospective study with [18F]F-FAPI-42 and [18F]F-FAPI-74. Mol Pharm. 2025;22(3):16264\u20131632. https:\/\/doi.org\/10.1021\/acs.molpharmceut.4c01360.","journal-title":"Mol Pharm"},{"key":"411_CR48","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13550-024-01191-6","volume":"14","author":"CD Van der Heide","year":"2024","unstructured":"Van der Heide CD, Campeiro JD, Ruigrok EAM, Van den Brink L, Ponnala S, Hillier SM, Dalm SU. In vitro and ex vivo evaluation of preclinical models for FAP-targeted theranostics: differences and relevance for Radiotracer evaluation. EJNMMI Res. 2024;14:125. https:\/\/doi.org\/10.1186\/s13550-024-01191-6.","journal-title":"EJNMMI Res"}],"container-title":["EJNMMI Radiopharmacy and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-025-00411-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-025-00411-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-025-00411-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T13:02:56Z","timestamp":1768914176000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41181-025-00411-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,14]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["411"],"URL":"https:\/\/doi.org\/10.1186\/s41181-025-00411-1","relation":{"references":[{"id-type":"doi","id":"10.1016\/j.nucmedbio.2023.108338","asserted-by":"subject"}]},"ISSN":["2365-421X"],"issn-type":[{"value":"2365-421X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,14]]},"assertion":[{"value":"15 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures were approved by the KU Leuven ethical review board (ethical approval reference P054\/2021). The clinical study (FAPIDO trial) is performed at University Hospital Leuven after approval by the Ethics Committee. (ClinicalTrials.gov identifier, NCT06782412).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Subject gave written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"L.T., C.W., and R.G. are employed by Trasis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}